Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis

Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis


A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.

Widely used osteoporosis drug may prevent breast, lung, and colon cancers


The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast, and colon cancers, according to two recent studies.

Bisphosphonates linked to lower endometrial cancer risk

Bisphosphonates linked to lower endometrial cancer risk

Nitrogen-containing bisphosphonates have been associated with reduced risk of endometrial cancer, according to research.

Capecitabine does not improve survival in elderly patients with early stage breast cancer


In elderly patients with moderate- to high-risk early stage breast cancer for whom standard chemotherapy is too toxic, capecitabine did not improve outcomes when tested as monotherapy, according to recent data.

Bisphosphonate use may not prevent breast cancer

Bisphosphonate use may not prevent breast cancer

Data from two randomized controlled trials suggest that bisphosphonate use does not protect against postmenopausal breast cancer, according to research.

Chemoresistant breast cancer outcomes not improved by bisphosphonate treatment


Treatment with zoledronate, a bisphosphonate, did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase 3 clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

Bisphosphonates reduce fractures, pain of multiple myeloma

Adding bisphosphonates to myeloma treatment decreases fractures of the vertebra and bone pain, affirm the results of a review of 20 trials.

Zoledronic acid continues to improve survival in premenopausal breast cancer

Long-term follow-up data suggest that adjuvant zoledronic acid results in highly significant disease-free and overall survival, mainly in patients with low levels of estrogen.

Bevacizumab label now warns of ovarian, osteonecrosis risks

The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.

Bisphosphonate therapy in breast cancer may help only older women

A large study has found that the routine use of zoledronic acid in the adjuvant management of breast cancer is not beneficial, but might extend survival in a subset of postmenopausal women.

Hypercalcemia in cancer patients

Hypercalcemia is the most common metabolic complication associated with malignancy and associated with poor prognosis; treatment is important for symptom palliation

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs